Computational Peptide Design
Developing Next-generation Therapeutics
About Us
Aplomex a computational start-up focused on the discovery, design, and development of novel constrained peptides as next-generation therapeutics for the treatment of chronic and metabolic diseases.
​
Our founders are scientists from A*STAR, Singapore who have more than three decades of experience in molecular modelling, design and simulations, having worked extensively with academia, clinical, biotech and pharma partners.
​
Aplomex is interested to partner with pharmaceutical companies to apply its computational platform for development of peptide based drug molecules directed at targets of interest.
​
We also provide state-of-the-art molecular modeling services to life science research institutions and start-ups, pharmaceutical or biotech companies.
​
Meet the Team
Aplomex founders are scientists from the Agency for Science, Technology and Research (A*STAR), based in Singapore, with several years of experience in novel drug discovery
Chandra Verma
Co-Founder
Srinivasaraghavan Kannan
Co-Founder
Drug modalities
Peptides: The Balanced Molecule
peptide
large
molecule
small
molecule
Peptides bridge the gap between small molecules and large molecules (biologics) with characteristics of high affinity, specificity, cell permeability, biocompatibility, and lower toxicity.
​
However, their applicability as therapeutics is limited due to their poor chemical and physical stability, short half-life, and limited cell permeability.
Our Platform
Our proprietary in-silico peptide design platform (PepDeSim) is a validated state-of-the-art computational platform for rapid discovery and development of novel constrained peptides.
"PepDeSim" can be applied to any target of interest ranging from extracellular to trans-membrane and intracellular proteins.
​
Aplomex utilizes its computational platform for the discovery of novel constrained peptide hit molecules and further development of those into preclinical candidates.
​
​
Our Strategy
3R Strategy
3D Strategy
These highly specific constrained peptides are much smaller than biologics, enabling more convenient routes of administration. The nature of the constrained peptides (relatively smaller size, resistance to harsh conditions such as stomach acids/digestion and intestinal absorption) offers the possibility of oral administration. The constrained peptides have the potential to become next generation orally-available peptide drugs.
Constrained Peptides - The Balanced Peptide Drug
Constrained peptides are a new class of molecules that combine the diversity and specificity of antibodies with the pharmacological properties of small, synthetic molecules. With its potentially improved tissue penetration and ability to modulate the undruggable protein-protein interactions (PPIs) constrained peptides expand the druggable world.
Service
We apply state-of-the-art computational methods to provide high quality, efficient and cost-effective molecular modeling services to assist in diverse aspects of your research and development.
Our Expertise
​
-
Molecular modeling and molecular dynamics simulation of biomolecules and their complexes
-
Identification of potential orthosteric, allosteric and novel cryptic pockets in biomolecules
-
Structure-based virtual screening to discover potential hit molecules, and further optimization
-
Identification and characterization of protein-protein interactions (PPI).
-
In-silico docking for modeling protein-peptide complexes
-
Protein and peptide (peptidomimetics) design, engineering and optimization
Our Service Model
​
-
Customized project timelines (FTE and project-based).
-
IPs generated under the projects remain with the client.
-
Open to academic collaborations.
-
Manage compound procurement including synthesis of small molecules, peptides, peptidomimetics, and in-vitro, cell-based, in-vivo assays (with Third Party Partners).
